Stem cell trial for kids with arthritis pulled before it started
NCT ID NCT06623240
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test whether infusions of stem cells from donated fat tissue could safely improve symptoms of juvenile idiopathic arthritis in children aged 2 to 17. The trial was a phase 2, randomized, double-blind, placebo-controlled crossover study, but it was withdrawn before any participants were enrolled. No results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs)
- What this could lead to
- If this approach worked, it could point toward a new way to control juvenile arthritis without lifelong medication.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. Stem cell treatments for arthritis are still experimental and may not work or could cause side effects like allergic reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hope Biosciences Research Foundation
Sugar Land, Texas, 77478, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease arthritis in kids?
- Knee injection study hopes to ease arthritis pain in children
- Can an extra shot boost COVID protection in autoimmune patients?
- Zoom yoga for young arthritis patients: a new hope?
- Can we predict chronic pain in teens? new study seeks answers
- New hope for kids with arthritis: Long-Term drug study launches